Mesenchymal Stem Cells
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Mesenchymal Stem Cells is an early-stage landscape with 0 programs across 9 companies. The most active players are Mario Negri Institute for Pharmacological Research, Sclnow Biotechnology Co., Ltd., Shanghai IxCell Biotechnology Co., LTD.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Mario Negri Institute for Pharmacological Research
0 programs
Sclnow Biotechnology Co., Ltd.
0 programs
Shanghai IxCell Biotechnology Co., LTD
0 programs
Meridigen Biotech Co., Ltd.
0 programs
Celltex Therapeutics Corporation
0 programs
Hexun Biosciences Co., LTD.
0 programs
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
118
clinical trials
Clinical Trials
Trial Activity
118 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)